Literature DB >> 30504618

Current Status of Azole-resistant Aspergillus fumigatus Isolates in East Asia.

Daisuke Hagiwara1,2.   

Abstract

Aspergillus fumigatus is a saprophytic fungus that is a major causative pathogen for aspergillosis. Only a few classes of antifungals are used for treating this life-threatening fungal infection. Azoles are the first-line drugs and are widely used for the management and prophylaxis of aspergillosis. An emerging issue is the increasing incidence of resistant isolates worldwide. In particular, environmentally derived tandem-repeat-type azole-resistant mutations, such as Cyp51A TR34/L98H, and Cyp51A TR46/Y121F/T289A, have emerged over the last decade. In particular, azole-resistant isolates were prevalent in clinical settings in European countries; many of the reports are from the Netherlands, UK, and Germany. In contrast, reports on azole-resistant A. fumigatus isolates from East Asian countries are still few and have only recently begun to increase. Herein, all literature on East Asian azole-resistant A. fumigatus isolates were reviewed, and a complete list of resistant isolates from China, Japan, Taiwan, and Korea is provided. As of this report, the total numbers of tandem-repeat-type azole-resistant isolates are 26, 3, 32, and 1 in China, Japan, Taiwan, and Korea, respectively.

Entities:  

Keywords:  Aspergillus fumigatus; Cyp51A; azole resistance; mutation

Mesh:

Substances:

Year:  2018        PMID: 30504618     DOI: 10.3314/mmj.18.010

Source DB:  PubMed          Journal:  Med Mycol J


  2 in total

1.  Hospital Environment as a Source of Azole-Resistant Aspergillus fumigatus Strains with TR34/L98H and G448S Cyp51A Mutations.

Authors:  Irene Gonzalez-Jimenez; Jose Lucio; Maria Dolores Menéndez-Fraga; Emilia Mellado; Teresa Peláez
Journal:  J Fungi (Basel)       Date:  2021-01-02

2.  Identification of Novel Mutations Contributing to Azole Tolerance of Aspergillus fumigatus through In Vitro Exposure to Tebuconazole.

Authors:  Takahito Toyotome; Kenji Onishi; Mio Sato; Yoko Kusuya; Daisuke Hagiwara; Akira Watanabe; Hiroki Takahashi
Journal:  Antimicrob Agents Chemother       Date:  2021-08-17       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.